WO2002049501A3 - Local regional chemotherapy and radiotherapy using in situ hydrogel - Google Patents

Local regional chemotherapy and radiotherapy using in situ hydrogel Download PDF

Info

Publication number
WO2002049501A3
WO2002049501A3 PCT/US2001/049087 US0149087W WO0249501A3 WO 2002049501 A3 WO2002049501 A3 WO 2002049501A3 US 0149087 W US0149087 W US 0149087W WO 0249501 A3 WO0249501 A3 WO 0249501A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
situ
radiotherapy
hydrogel
local regional
Prior art date
Application number
PCT/US2001/049087
Other languages
French (fr)
Other versions
WO2002049501A2 (en
Inventor
David J Yang
Dong-Fang Yu
Ali Azhdarinia
Tommy L Lee
E Edmund Kim
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Priority to DK01991306.0T priority Critical patent/DK1355566T3/en
Priority to AU3104102A priority patent/AU3104102A/en
Priority to EP01991306A priority patent/EP1355566B1/en
Priority to CA2432797A priority patent/CA2432797C/en
Priority to JP2002550847A priority patent/JP2004528278A/en
Publication of WO2002049501A2 publication Critical patent/WO2002049501A2/en
Publication of WO2002049501A3 publication Critical patent/WO2002049501A3/en
Priority to HK04102790.4A priority patent/HK1060283A1/en
Priority to AU2007201748A priority patent/AU2007201748B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/729—Agar; Agarose; Agaropectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Methods regarding local regional treatment in situ for an individual, such as of a tumor, are provided herein. A hydrogel composition is generated in situ in the tumor by administering a polymer, such as a polysaccharide or a polymino acid, with a therapic agent, such as a radionuclide or a drug, and administering a cross-linking agent. The hydrogel/therapeutic agent composition is retained in the tumor for safe and efficient tumor therapy. Alternatively, a hydrogel composition is generated in situ in an artery which nourishes a tumor to occlude the artery.
PCT/US2001/049087 2000-12-18 2001-12-18 Local regional chemotherapy and radiotherapy using in situ hydrogel WO2002049501A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK01991306.0T DK1355566T3 (en) 2000-12-18 2001-12-18 Local regional chemotherapy and radiotherapy using hydrogel in situ
AU3104102A AU3104102A (en) 2000-12-18 2001-12-18 Local regional chemotherapy and radiotherapy using in situ hydrogel
EP01991306A EP1355566B1 (en) 2000-12-18 2001-12-18 Local regional chemotherapy and radiotherapy using in situ hydrogel
CA2432797A CA2432797C (en) 2000-12-18 2001-12-18 Local regional chemotherapy and radiotherapy using in situ hydrogel
JP2002550847A JP2004528278A (en) 2000-12-18 2001-12-18 Localized area chemotherapy and radiation treatment using in situ hydrogel
HK04102790.4A HK1060283A1 (en) 2000-12-18 2004-04-21 Local regional chemotherapy and radiotherapy using in situ hydrogel
AU2007201748A AU2007201748B2 (en) 2000-12-18 2007-04-19 Local regional chemotherapy and radiotherapy using in situ hydrogel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25651400P 2000-12-18 2000-12-18
US60/256,514 2000-12-18

Publications (2)

Publication Number Publication Date
WO2002049501A2 WO2002049501A2 (en) 2002-06-27
WO2002049501A3 true WO2002049501A3 (en) 2003-09-04

Family

ID=22972510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/049087 WO2002049501A2 (en) 2000-12-18 2001-12-18 Local regional chemotherapy and radiotherapy using in situ hydrogel

Country Status (8)

Country Link
US (2) US7008633B2 (en)
EP (1) EP1355566B1 (en)
JP (1) JP2004528278A (en)
AU (1) AU3104102A (en)
CA (1) CA2432797C (en)
DK (1) DK1355566T3 (en)
HK (1) HK1060283A1 (en)
WO (1) WO2002049501A2 (en)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
AU3104102A (en) * 2000-12-18 2002-07-01 Univ Texas Local regional chemotherapy and radiotherapy using in situ hydrogel
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
JP2007502296A (en) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Robust pellet
WO2005016278A2 (en) * 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
EP1670449B1 (en) 2003-09-15 2012-06-27 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use in angiogenesis
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
WO2005099367A2 (en) * 2004-04-16 2005-10-27 Critical Care Innovations, Inc. Systems and methods for improving image-guided tissue ablation
US20120143167A1 (en) * 2004-04-16 2012-06-07 Morrison Dennis R Methods For Improved Cryo-Chemotherapy Tissue Ablation
JP2008505124A (en) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション Pulse delivery tablets
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
CN1319525C (en) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 Taxinol-sodium alginate micro ball vascular embolism agent and its preparation
EA013680B1 (en) * 2005-04-15 2010-06-30 Бейцзин Шенияо Сайнс Энд Текнолоджи Девелопмент Ко., Лтд. Microspherical vascular embolus of sodium alginate containing a gynecological pharmaceutics and preparation thereof
WO2007011674A2 (en) * 2005-07-15 2007-01-25 Baker Donald J Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals
WO2007033082A2 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20080260771A1 (en) * 2006-09-12 2008-10-23 Olalde Rangel Jose A Prostate disorder(s) phyto-nutraceutical synergistic composition
US9446087B2 (en) * 2006-10-24 2016-09-20 David W. Krempin Anti-resorptive and bone building dietary supplements and methods of use
AU2007353426A1 (en) 2006-12-22 2008-11-20 Albany College Of Pharmacy And Health Sciences Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US7850382B2 (en) * 2007-01-18 2010-12-14 Sanford, L.P. Valve made from two materials and writing utensil with retractable tip incorporating same
US7488130B2 (en) * 2007-02-01 2009-02-10 Sanford, L.P. Seal assembly for retractable instrument
US8226312B2 (en) * 2008-03-28 2012-07-24 Sanford, L.P. Valve door having a force directing component and retractable instruments comprising same
EP2274422B1 (en) * 2008-04-17 2017-03-15 Anaeropharma Science, Inc. Expression vector
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
JP2010104694A (en) 2008-10-31 2010-05-13 Mitsubishi Heavy Ind Ltd Device for detecting abnormality of auxiliary artificial heart, method for detecting abnormality of auxiliary artificial heart, and abnormality detection program
BRPI0921494A2 (en) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd method of planning a underground forming sampling operation, method of controlling a underground forming sampling operation, method of controlling a drilling operation for an underground formation, and method of sampling during the drilling operation.
US8221012B2 (en) * 2008-11-07 2012-07-17 Sanford, L.P. Retractable instruments comprising a one-piece valve door actuating assembly
AU2009322999A1 (en) * 2008-12-01 2011-06-30 Invasc Therapeutics, Inc. Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
US20100135945A1 (en) * 2008-12-02 2010-06-03 Kreations By Kristin, Llc Gymnema-containing lip balm compositions and associated methods
CH702736B1 (en) * 2008-12-31 2012-12-14 Obschestvo S Organichennoi Otvetstvennostju Scient Company Flamena Phospholipid emulsion which includes Dihydroquerzetin.
US8393814B2 (en) * 2009-01-30 2013-03-12 Sanford, L.P. Retractable instrument having a two stage protraction/retraction sequence
WO2010098652A1 (en) * 2009-02-24 2010-09-02 Universiti Putra Malaysia Cola nitida ( cola nut ) as an anticancer agent
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
US8663210B2 (en) * 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
CA2765792C (en) 2009-06-17 2017-03-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
CN102470180A (en) * 2009-07-09 2012-05-23 聚合物Crc有限公司 Biopolymer hybrid gel-depot delivery system
US7897184B1 (en) * 2009-08-13 2011-03-01 Access Business Group International Llc Topical composition with skin lightening effect
EP2493314B1 (en) 2009-10-30 2020-04-08 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
CN102741336B (en) 2009-12-01 2014-03-19 株式会社普利司通 Modified rubber compositions and methods of preparation
EP2530150A4 (en) * 2010-01-29 2013-10-23 Anaeropharma Science Inc Transformation plasmid
EP2552416B1 (en) 2010-03-29 2017-10-25 Evonik Corporation Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
CN102462664A (en) * 2010-11-18 2012-05-23 华侨大学 Sulfonyl sulfhydryl chitosan interventional chemoembolization slow-release microsphere and preparation method thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
CA2839727C (en) * 2011-07-07 2023-10-17 Research Cancer Institute Of America Systems, methods, and formulations for treating cancer
RU2489147C2 (en) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Local pharmaceutical antibacterial composition of active biometallic complexes
CA2970639C (en) 2012-01-12 2022-04-26 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
WO2013112381A2 (en) 2012-01-24 2013-08-01 Bvw Holding Ag New class of anti-adhesion hydrogels with healing aspects
TWI503132B (en) * 2012-04-27 2015-10-11 Univ Nat Cheng Kung Pharmaceutical microsphere for embolization
NL2009688C2 (en) * 2012-10-24 2014-04-29 Nucletron Operations Bv A settable radioactive gel, a method of manufacturing a settable radioactive gel, a device for manufacturing a settable radioactive gel.
US20140194370A1 (en) 2013-01-08 2014-07-10 University Of Utah Research Foundation Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer
CN103157129B (en) * 2013-03-13 2014-10-01 上海大学 polyamino acid/hydroxyapatite composite hydrogel for bone repair and preparation method thereof
DK2968484T3 (en) 2013-03-15 2021-02-22 Biospecifics Tech Corporation Treatment method and product for uterine fibroids that use purified collagenase
ITRM20130312A1 (en) * 2013-05-29 2014-11-30 Aboca Spa Societa Agricola EXTRACT OF CYNARA SPP. AND ITS USES.
TWM467462U (en) * 2013-06-05 2013-12-11 Chin-Tung Lee Chitin modified ethanol liposome carrier structure
PT2898891T (en) * 2013-08-13 2020-07-30 Natreon Inc Terminalia chebula and terminalia bellerica extracts for inhibition of xanthine oxidase
CN103751102A (en) 2014-01-15 2014-04-30 上海交通大学 Collagenase thermoresponsive hydrogel and preparation method and application of hydrogel
CN104950005A (en) * 2014-03-26 2015-09-30 中国科学院大连化学物理研究所 Qualitative analysis method for distinguishing water contents of lightly dried sea cucumber, salt dried sea cucumber and expanded sea cucumber
CN105647825B (en) * 2014-11-13 2019-05-21 中国科学院大连化学物理研究所 Method that is a kind of while improving spiral algal biomass and polysaccharide yield
ES2928503T3 (en) 2014-12-24 2022-11-18 Univ North Carolina Chapel Hill Combined local delivery of therapeutic agents using interventional and radiation devices
CN104698021B (en) * 2015-01-22 2017-01-18 天津中医药大学 Method for detecting content of primary metabolic components in astragalus injection
EP3265177B1 (en) * 2015-01-22 2023-06-14 Grey Pacific Labs, LLC Formulations of hydrophilic compounds
US9919016B2 (en) * 2015-02-10 2018-03-20 Bilal Qizilbash Product and method of deploying kale derivatives for anti-cancer effects
EP3291838A4 (en) * 2015-05-05 2019-01-02 B.G. Negev Technologies and Applications Ltd. Anionic nanoparticles for use in the delivery of anionic small molecule drugs
WO2017090047A1 (en) 2015-11-27 2017-06-01 Technology Innovation Momentum Fund (Israel) Limited Partnership Glucosamine and derivatives thereof in imaging
WO2017214299A1 (en) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc NON-CLEAVABLE POLYMER CONJUGATED WITH αvβ3 INTEGRIN THYROID ANTAGONISTS
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
CN106834682A (en) * 2017-01-20 2017-06-13 卜琰 A kind of method for extracting germanium dechlorination in solution of zinc sulfate
CN115969318A (en) 2017-03-01 2023-04-18 恩多风投有限公司 Device and method for evaluating and treating cellulite
MA49265A (en) 2017-03-22 2020-02-05 Ascendis Pharma As Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
KR20240001279A (en) 2017-03-28 2024-01-03 엔도 벤쳐즈 리미티드 Improved method of producing collagenase
US10849914B2 (en) 2017-06-12 2020-12-01 University Of Utah Research Foundation Methods for producing chemoembolic agents for the delivery of anti-cancer agents
CN107213479B (en) 2017-06-22 2018-12-28 苏州杰纳生物科技有限公司 A kind of composition and purposes comprising catalase
CN107375939B (en) * 2017-07-19 2021-02-23 中国药科大学 Amphotericin B polypeptide hydrogel drug-loading system for treating fungal infection
EP3501553A1 (en) * 2017-12-21 2019-06-26 Association for the Advancement of Tissue Engineering and Cell based Technologies & Therapies (A4TEC) - Associação Hydrogel comprising manganese, methods and uses thereof
US11446348B2 (en) 2017-12-30 2022-09-20 Bilal Qizilbash Vegetable powders, methods for manufacturing vegetable powders, and kits thereof
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020150391A1 (en) * 2019-01-15 2020-07-23 Falcon Therapeutics, Inc. Engineered stem cell constructs and uses thereof
CN109758675A (en) * 2019-01-29 2019-05-17 青岛中腾生物技术有限公司 A kind of self-healing medical gel
WO2021061944A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Creatine for immunotherapy
WO2021076618A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
CN111557968A (en) * 2020-03-17 2020-08-21 常州市中医医院 Traditional Chinese medicine compound composition with function of regulating immunity and application thereof
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
CN112457857A (en) * 2020-10-31 2021-03-09 兰州资源环境职业技术学院 Soil conditioner for removing heavy metals in coal mining area
US20230094016A1 (en) 2021-09-29 2023-03-30 Mayo Foundation For Medical Education And Research Injectable shear-thinning hydrogel containing polypeptide therapeutic agent for enhanced tumor therapy
NO20211268A1 (en) * 2021-10-21 2023-04-24 Blue Wave Therapeutics Gmbh Peptide-coupled alginate gels comprising radionuclides
CN114224823B (en) * 2021-11-02 2023-12-05 南京医科大学 Brain glioma drug delivery system integrating chemotherapy, photodynamic therapy and chemo-dynamic therapy and preparation method thereof
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587268A (en) * 1980-09-03 1986-05-06 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of osteitis
US5470843A (en) * 1992-12-11 1995-11-28 Hoechst Aktiengesellschaft Carbohydrate-containing polymers, their preparation and use
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
BR8606735A (en) * 1985-06-19 1987-08-11 Exxon Chemical Patents Inc THERMOPLASTIC ELASTOMER COMPOSITION
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
NO171069C (en) * 1990-05-29 1993-01-20 Protan Biopolymer As COVALENT CIRCUIT, STRONGLY SWELLING ALKALIMETAL AND AMMONIUM ALGINATE GELS, AND PROCEDURES FOR PREPARING THEREOF
US5257970A (en) 1992-04-09 1993-11-02 Health Research, Inc. In situ photodynamic therapy
JP3107488B2 (en) 1993-09-29 2000-11-06 株式会社資生堂 Sustained-release preparation and embolic agent using cross-linked hyaluronic acid
CA2176933A1 (en) * 1993-11-18 1995-05-26 Yan Chen Controlled release preparation
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
AU697045B2 (en) * 1995-01-16 1998-09-24 Baxter International Inc. Self-supporting sheet-like material of cross-linked fibrin for preventing post- operative adhesions
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
CN1213316A (en) * 1996-03-11 1999-04-07 富克尔公司 Polymeric delivery of radionuclides and radiopharmaceuticals
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
JP4116683B2 (en) 1997-02-28 2008-07-09 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Sustained release topical delivery formulation
US5854382A (en) * 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6146373A (en) 1997-10-17 2000-11-14 Micro Therapeutics, Inc. Catheter system and method for injection of a liquid embolic composition and a solidification agent
JP2002519333A (en) 1998-06-30 2002-07-02 アムジエン・インコーポレーテツド Thermosensitive biodegradable hydrogels for sustained release delivery of biologically active substances
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU3104102A (en) * 2000-12-18 2002-07-01 Univ Texas Local regional chemotherapy and radiotherapy using in situ hydrogel

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587268A (en) * 1980-09-03 1986-05-06 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of osteitis
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5470843A (en) * 1992-12-11 1995-11-28 Hoechst Aktiengesellschaft Carbohydrate-containing polymers, their preparation and use
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1355566A4 *

Also Published As

Publication number Publication date
US20050227910A1 (en) 2005-10-13
EP1355566B1 (en) 2012-11-28
CA2432797A1 (en) 2002-06-27
CA2432797C (en) 2014-02-04
DK1355566T3 (en) 2013-03-04
EP1355566A2 (en) 2003-10-29
WO2002049501A2 (en) 2002-06-27
EP1355566A4 (en) 2007-10-24
AU3104102A (en) 2002-07-01
JP2004528278A (en) 2004-09-16
US20050208138A1 (en) 2005-09-22
HK1060283A1 (en) 2004-08-06
US7008633B2 (en) 2006-03-07

Similar Documents

Publication Publication Date Title
WO2002049501A3 (en) Local regional chemotherapy and radiotherapy using in situ hydrogel
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
HK1089378A1 (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
MX2007003506A (en) Cancer combination therapy comprising azd2171 and imatinib.
MX2007003505A (en) Combination comprising zd6474 and an imatinib.
MXPA04004355A (en) Combination therapy comprising zd6474 and a taxane.
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2007071958A3 (en) Combination of zd6474 and pemetrexed
BR0313117A (en) Method for producing a vascular and / or antiangiogenic permeability reducing effect in a warm-blooded animal such as a human, method for treating cancer in a warm-blooded animal such as a human, pharmaceutical composition, kit, and , use of zd6474 or a pharmaceutically acceptable salt thereof and zd1839 or a pharmaceutically acceptable salt thereof
WO2006048633A3 (en) Combination comprising zd6474 and an antiandrogen
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
WO2004071397A3 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
HK1089384A1 (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine
WO2005092385A3 (en) Combination therapy of azd2171 and a taxane
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
EE200200549A (en) Split dose therapy with vascular damaging activity
WO2004112801A3 (en) Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer
EP1547596A4 (en) Medicinal composition and method for treating malignant tumor and utilization thereof
ATE339209T1 (en) COMBINATION THERAPY WITH GEMZITABINE AND ZD6126

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2432797

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002550847

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002231041

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001991306

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2001991306

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002231041

Country of ref document: AU